nature chemistry

Article

https://doi.org/10.1038/s41557-026-02072-2

Hetero[3.1.1]propellanes

Received: 22 March 2025

Accepted: 14 January 2026

Rebecca I. Revie[1], Ayan Dasgupta[1], Yasmine Biddick[1], Kirsten E. Christensen[1], Russell C. Smith[2] & Edward A. Anderson[1]

[*n*.1.1]Propellanes are key precursors to bicyclo[*n*.1.1]alkanes, rigid small-ring hydrocarbons that have emerged as important building blocks in contemporary drug design as bioisosteres for disubstituted benzene rings. [*n*.1.1]Propellanes featuring heterocyclic rings could enable the direct synthesis of a wide diversity of bridged bicyclic heterocycles, which should exhibit superior physicochemical profiles compared to their established carbocyclic analogues. Here we report the unified synthesis of a family of heterocyclic [3.1.1]propellanes featuring oxygen, nitrogen and sulfur heteroatoms in the three-carbon bridge. The approaches we have developed are necessarily distinct from the established routes to carbocyclic propellanes, and utilize a common precursor that is conveniently assembled on a multigram scale via rhodium-catalysed cyclopropanation. These hetero[3.1.1]propellanes undergo a range of radical ring-opening reactions, affording bridged heterocycles that are of high utility in drug-discovery programmes.

Small-ring bridged bicyclic organic molecules have become valuable frameworks in modern drug design[1,2]. The rigidity of these motifs results in well-defined positioning of their substituents in three-dimensional (3D) chemical space, with additional benefits to physicochemical properties such as solubility and metabolic stability arising from their increased sp^3 character[3] compared to traditional drug fragments such as aromatic rings[4,5]. In certain cases, these bicyclic systems have been specifically designed to mimic the geometries of arenes. For instance, bridgehead-disubstituted bicyclo[1.1.1]pentanes (BCPs, Fig. 1a) and bicyclo[3.1.1]heptanes (BCHeps) have been shown to act as bioisosteres for *para*- and *meta*-substituted benzenes, respectively, due to the equivalent exit vectors of their bridgehead substituents compared to their aromatic counterparts. Key examples include the BCP analogue of the γ-secretase inhibitor avagacestat[6], and the BCHep analogue of the anticancer agent sonidegib[7]. These motifs are most readily accessed by ring-opening reactions of [1.1.1]- and [3.1.1]propellanes (**1**)[7–9], where under radical or anionic conditions, cleavage of the central C–C bond enables the installation of a range of substituents at the bridgehead positions[10–12]. Over the past decade, more than 20,000 BCPs have been forged from [1.1.1]propellane alone (Fig. 1a), underlining the importance of propellanes in organic and medicinal chemistry[13].

One drawback of the BCHep scaffold compared to its BCP relative is its higher lipophilicity, which derives from the inclusion of two additional methylene (CH_2) groups in its six-membered ring. This results in similar calculated values for the logarithm of the octanol/water partition coefficient (clog*P*) for BCHeps compared to the analogous aromatic compounds[7], limiting the performance of these motifs in drug candidates. A solution to this problem is the introduction of a heteroatom into the bicyclo[3.1.1]heptane framework, which in the case of oxa-BCHeps has been shown to enhance physicochemical properties compared to their carbocyclic parents[14–16]. Furthermore, aza-BCHeps have been proposed as bioisosteres for pyridines, which are commonplace heteroaromatic rings[14], and other structures such as oxa- and thia-BCHeps represent an unexplored chemical space in drug design. As such, rapid and diversifying entries to hetero-BCHeps are highly desirable.

Existing approaches to these valuable heterocyclic frameworks have limitations. For example, routes to 3-azacyclic analogues (3-aza-BCHeps, Fig. 1b) have been reported through the stepwise insertion of heteroatom-containing three-atom motifs such as azomethine ylids[17], isocyanides[18] and vinyl azides[19] into the inter-bridgehead bond of bicyclo[1.1.0]butanes (BCBs)[20,21]. Although successfully generating the 3-aza-BCHep scaffold, these methods display limited diversity in

---

[1] Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Oxford, UK. [2] Drug Discovery Science and Technology (DDST), AbbVie, North Chicago, IL, USA. ✉e-mail: edward.anderson@chem.ox.ac.uk



Fig. 1 | Bridged bicyclic hydrocarbons as bioisosteres of benzene rings, and heterocyclic analogues based on the bicyclo[3.1.1]heptane framework. **a**, Carbocyclic [*n*.1.1]propellanes **1** are versatile precursors for the synthesis of bicyclo[*n*.1.1]alkanes such as BCPs and BCHeps, which serve as bioisosteres for disubstituted benzene rings in drug design. The importance of [*n*.1.1]propellanes is illustrated by the rapid growth in BCPs reported in the Reaxys database over the last 15 years, almost all of which originate from [1.1.1]propellane. **b**, Existing routes to 3-azabicyclo[3.1.1]heptanes based on three-atom insertions into BCBs necessarily introduce specific substitution patterns, as highlighted in maroon. Ring-opening of spirocyclic oxetanes provides an alternative route but again results in specific product substituents. **c**, The 3-hetero[3.1.1]propellanes **3**–**5** can be accessed on a gram scale in five to seven synthetic steps from 2,3-dibromopropene and diazomalonate. These propellanes offer an attractive entry to a wide variety of bridgehead substituted 3-hetero-BCHeps that exhibit superior physicochemical profiles compared to carbocyclic BCHeps.

the functionalities that can be introduced at the 3-aza-BCHep bridgehead positions. This is due to restrictions in BCB preparation and stability, and indeed the subsequent insertion reaction pathways, necessitating a predetermined electron-withdrawing group and an aromatic ring (or proton) on the BCB bridgehead atoms (highlighted in maroon). These reactions also install specific substituents on their three-atom bridges in addition to the heteroatom itself, which may not be desired for a given application. An alternative strategy, described by Mykhailiuk and colleagues[14,15] and Ryabchuk and colleagues[16], involves the ring-opening/cyclization of an amine- or hydroxy-functionalized spirocyclic cyclobutane-oxetane **2**, which invariably positions a hydroxymethyl group at one of the bridgehead carbon atoms. Despite a handful of related scaffolds being accessible (albeit also with limitations in substituent scope)[19,22–28], no single method offers unified access to a family of hetero-BCHeps in a manner that enables late-stage bridgehead substituent diversification. This is an important goal, as many hetero-BCHeps have no analogy in heteroaromatic chemical space (for example, oxa- and thia-scaffolds), and therefore offer many opportunities in drug design.

Heteropropellanes (**3**–**5**, Fig. 1c) would be highly appealing as alternative precursors to hetero-BCHeps. However, despite more than 50 years of research into propellane chemistry[13], hetero[*n*.1.1]propellanes have so far eluded synthesis. The physical and chemical properties of these strained heteropropellanes are therefore entirely uncharted, and comparison with well-established carbocyclic analogues is an exciting prospect. Furthermore, given the importance of the carbocyclic [1.1.1] and [3.1.1]propellanes in drug design, the availability of such structures would probably be of great utility in medicinal and biological chemistry research. Here we describe a general, scalable strategy for the synthesis of hetero[3.1.1]propellanes **3**–**5**, members of a 'small ring' heteropropellane family that have not previously succumbed to chemical synthesis. We show that these molecules can exhibit marked stability compared to their carbocyclic analogues, and are conveniently isolated without recourse to distillation, as has typically been required for carbocyclic propellanes. We also disclose their ring-opening functionalization using a variety of radical-based methods, which offers access to valuable 3-hetero-BCHeps, including the late-stage functionalization of biologically relevant molecules.

Results

Heteropropellane synthesis

Our work began with the development of a viable route to 3-oxa[3.1.1]propellane (Fig. 2). After exploring a number of potential strategies (Supplementary Section 2), we identified a route that began with a rhodium-catalysed cyclopropanation of 2,3-dibromopropene with dimethyl diazomalonate (**6**). This cyclopropanation benefited from use of the bulky triphenylacetate (TPA)-ligated rhodium catalyst, and could be performed on a decagram scale at just 0.05 mol% catalyst loading (68% yield). Reduction of the resulting cyclopropane diester **7** proceeded optimally using diisobutylaluminum hydride (DIBALH), and direct treatment of the product diol **8** with potassium hydroxide effected cyclization of the alcohol *syn* to the bromomethyl group to form tetrahydrofuran (THF) **9** (83% over two steps). The residual alcohol in **9** was then converted to the corresponding bromide **10** under Appel-type conditions (74%). With this 3-oxa[3.1.1]propellane precursor in hand, we explored lithiation of the bridgehead bromide, a reaction that in this oxacyclic system carries a risk of β-elimination of the THF ring. We were therefore delighted to observe that on treatment of **10** with 1 equiv. of methyllithium in diethyl ether, cyclization proceeded smoothly at room temperature, affording a solution that consisted solely of the targeted 3-oxa[3.1.1]propellane **3** and bromomethane, along with lithium bromide (the latter as a fine precipitate). Purifications of carbocyclic propellanes typically involve co-distillation of the propellane from the reaction mixture with a solvent of similar



Fig. 2 | Scalable synthesis of 3-hetero-BCHeps. Synthetic routes to 3-oxa-, 3-thia- and 3-aza[3.1.1]propellanes (**3**–**5**) initiate with rhodium-catalysed cyclopropanation of 2,3-dibromopropene with diazomalonate. The structure of 3-aza[3.1.1]propellane **5** was determined using single-crystal X-ray diffraction (CCDC 2412510, displacement ellipsoids drawn at 50%).

boiling point. Pleasingly, we found that the reaction mixture was of sufficient purity that this was not necessary, and a solution of **3** in Et$_2$O could be conveniently obtained by the simple addition of NaHCO$_3$ (to quench any residual MeLi), followed by filtration through celite and partial concentration to remove bromomethane. This solution contained traces of LiBr, which did not affect subsequent reactivity, but could be removed if desired by co-distillation with dibutyl ether (Supplementary Section 5). Importantly, this route could be executed on a multigram scale (for example, reaction of 5 g of **10** afforded **3** in 74% yield). In a similar manner to carbocyclic propellanes, we found that ethereal solutions of 3-oxa[3.1.1]propellane could be stored in the dark at −20 °C under an inert atmosphere, and were stable for several months without degradation.

With 3-oxa[3.1.1]propellane in hand, we questioned whether we could leverage this synthetic route to access other heterocyclic [3.1.1] propellanes. We first addressed the synthesis of 3-thia[3.1.1]propellane by intercepting diol **8** with potassium thioacetate, whereby substitution of the bromomethyl group afforded thioester **11** (54% over two steps). After some investigation, we found that bromination of this diol offered the optimal means to convert the two alcohols into suitable leaving groups for propellane synthesis, with NBS/PPh$_3$ delivering dibromide **12** in 58% yield. Hydrolysis of the thioester (KOH) triggered cyclization to the tetrahydrothiophene **13** (95%), treatment of which with methyllithium effected lithiation of the bridgehead bromide, followed by cyclization to 3-thia[3.1.1]propellane **4** in 68% yield, which could also be isolated as a solution in diethyl ether.

The synthesis of 3-aza[3.1.1]propellane brings opportunities to functionalize the propellane framework with an additional substituent on the heteroatom. To establish the synthesis, we first considered an *N*-tosyl group, which we anticipated would prove tolerant of the synthetic route. In the event, we were able to identify a suitable path to the 3-aza[3.1.1]propellane **5** from cyclopropanation product **7**. Reaction of **7** with sodium azide (to give **14**, 96%), followed by Staudinger reduction using tri-*n*-butylphosphine, afforded the lactam ester **15** (61%). A screening of various reducing agents revealed that Red-Al was uniquely effective for reduction of the lactam ester to the corresponding pyrrolidine alcohol; direct *N*-tosylation gave the pyrrolidine sulfonamide **16** (40% over two steps). Following bromination of the residual alcohol (**17**, 92%), reaction with MeLi gave 3-*N*-Ts-[3.1.1] propellane **5** as a solution in THF. Remarkably, diffusion of an ether/pentane mixture into this solution afforded crystals of **5**, which, unlike carbocyclic propellanes, did not undergo spontaneous polymerization to a BCHep-staffane. Although not stable for a prolonged period, this enabled determination of the single-crystal X-ray structure, providing insight into the geometry of this small-ring propellane (Fig. 2; details are provided in Supplementary Section 7 and a further discussion of propellane stability in Supplementary Section 6). It is possible that the unexpected stability of this propellane can be ascribed to the inductive electron-withdrawing effect of the sulfonamide nitrogen atom, which renders the inter-bridgehead bond less electron-rich, reducing the usual destabilizing Pauli repulsion with adjacent C–C bonds[29].

Heteropropellane reactivity

With a selection of hetero[3.1.1]propellanes in hand, their reactivity was explored under a range of radical ring-opening conditions (Table 1). The atom transfer radical addition (ATRA) of carbon–halogen bonds across propellanes is one of the most versatile methods for ring-opening[30–32], and we were able to generate a range of oxa- and aza-BCHeps using

Table 1 | Ring-opening reactions of hetero[3.1.1]propellanes[a]



18a: X = O 69%[a], 82%[b]
18b: X = NTs 85%[a]
18c: 62%[b]
18d: 23%[a]
18e: X = O 58%[a], 75%[b]
18f: X = NTs 21%[a]
18g: 25%[b]
18h: 65%[b]
18i: 64%[b]
18j: 65%[b]
18k: 52%[b]
18l: 54%[b]
18m: X = NTs 42%[c]
18n: X = S 32%[a]
18o: 53%[d]
18p: 62%[e]
18q: 69%[f]
18r: X = O: 49%[g] + **18r′**: X = O: 7%[g]
18s: X = NTs: 32%[g] **18s′**: X = NTs: 22%[g]
18t: 58%[h]
18u: X = O 91%[i]
18v: X = S 42%[i]
18w: X = NTs 48%[i]
18x: 93%[i]
18y: 34%[i]
18z: 49%[i]
18aa: 61%[j]
18ab: 35%[b]
18ac: 47%[b]
18ad: 44%[b]

Reaction conditions: [a]BEt$_3$ (10 mol%) in Et$_2$O, 25 °C (for **18a**, **18b**, **18d–f** and **18n**); [b]Ir(ppy)$_3$ (2.5 mol%), ^{t}BuCN, blue LEDs (450–456 nm), 25 °C (for **18a**, **18c**, **18e**, **18g–l** and **18ab–ad**); [c]direct reaction with organohalide with no initiator; [d]iodomethylaziridine, Ir(ppy)$_3$ (2.5 mol%), ^{t}BuCN, blue LEDs (450–456 nm), 25 °C; [e]RSO$_2$Br, Et$_2$O, 25 °C; [f]RSO$_2$I, −5 °C, 10 min; [g]I$_2$, 25 °C; [h]*N*-phenylpyrrolidine, 4CzIPN (2.5 mol%), blue LEDs (440 nm), dimethylacetamide, 25 °C; [i]chalcogen or dichalcogen, 25 °C; [j]cysteine derivative, BEt$_3$ (10 mol%). The structure of **18i** was determined using single-crystal X-ray diffraction (CCDC 2412511, displacement ellipsoids drawn at 50%).

either triethylborane as initiator[31], or iridium photocatalysis[32]. This included the formation of iodo-hetero-BCHeps by the addition of electron-deficient (**18a–d**) and electron-rich (**18e**,**f**) alkyl radicals. In the former case, comparable yields were obtained for the addition of an acetyl radical to both oxa- and aza[3.1.1]propellanes (**3** and **5**), and for the latter, reaction with **3** proved superior. The addition of a benzyl radical (**18g**) and both unsaturated (pyridyl) and saturated (piperidine and azetidine) radicals on nitrogen heterocycles (**18h–j**), as well as C–Br bonds, also proved successful (**18k–n**). We further achieved the addition of heteroatom-centred radicals: an *N*-substituted oxa-BCHep (**18o**) was prepared by radical fragmentation of an iodomethyl aziridine[33], and halosulfonylation of 3-oxa[3.1.1]propellane was also achieved in good yields (**18p**,**q**)[34]. Treatment of 3-oxa- or 3-aza[3.1.1]propellane with iodine afforded a mixture of diiodo-BCHep (**18r**,**s**) and the corresponding [2]staffanes (**18r′**,**s′**) where, interestingly, the proportion of staffane was higher for the aza-BCHep; these adducts represent stable potential propellane precursors (see below). We also found that other radical addition methods could be applied, such as the addition of an α-amino radical via organophotoredox catalysis (**18t**)[35], and a range of chalcogen-substituted BCHeps (**18u–z**) were prepared by direct addition of the chalcogen or dichalcogen to the propellane[36–38]. We were able to demonstrate the wider potential of these heteropropellanes by the synthesis of pharmaceutically relevant compounds, including the cysteine-substituted oxa-BCHep **18aa**, galactopyranose derivative **18ab**, and pretilachlor derivative **18ac**. Finally, product **18ad** is an interesting example of a compound containing both a carbocyclic and heterocyclic BCHep.

These reactions revealed differences in behaviour between the various hetero[3.1.1]propellanes. In general, 3-aza[3.1.1]propellane-**5** was found to be less susceptible to ring-opening than 3-oxa[3.1.1] propellane **3**; while reacting efficiently with electron-deficient radicals, ring-opening of **5** with electron-rich species was less facile (c.f. **18e** versus **18f**), reflecting its greater stability (in some reactions, unreacted **5** could be observed in the crude reaction mixture). Reactions of 3-thia[3.1.1]propellane were limited to those with very efficient propagation steps, as bridgehead thia-BCHep radicals were otherwise found to be prone to fragmentation of the ring before interception with a halogen or hydrogen atom source—a process not previously witnessed



Fig. 3 | Further aspects of heteropropellane chemistry. a, Re-formation of propellanes from diiodo hetero-BCHeps and hetero-[2]staffanes. **b**, Examples of 3-aza[3.1.1]propellanes with alternative groups on the nitrogen, which are installed at the penultimate step of propellane synthesis. **c**, Application of 3-oxa[3.1.1] propellane to the synthesis of oxa-BCHep-sonidegib (**22**). **d**, Detosylation of aza-BCHep **18ac**. TMEDA, *N*,*N*,*N′N′*-tetramethylethylenediamine; HATU, hexafluorophosphate azabenzotriazole tetramethyl uronium.

in radical-based propellane chemistry. In these cases, increasing the concentration of the thiol substrate was found to improve yields due to rapid capture of the bridgehead radical (Supplementary Section 3 provides additional details for unsuccessful substrates, and Supplementary Section 5 provides details of thia-BCHep fragmentation).

While the dibromides **10**, **13** and **17** provide a convenient means to access the hetero[3.1.1]propellanes, we questioned whether diiodo-hetero-BCHeps might also be suitable precursors[39,40]. To validate this hypothesis, we treated the mixtures of diiodo-hetero-BCHep and staffane dimer obtained from iodination of 3-oxa[3.1.1]propellane (**18r**/**r′**) or 3-aza[3.1.1]propellane (**18s**/**s′**) with methyllithium (Fig. 3a), and found, in both cases, that the corresponding propellanes **3** and **5** were successfully reformed in excellent yields (100% and 83%, respectively). The presumed lithiated BCHep intermediates in this transformation carry the risk of β-elimination of the heteroatom; however, the only products observed were the propellanes. It is also notable that the hetero-staffane is equally susceptible to this fragmentation, despite the associated cost of C−C bond cleavage and presumed increase in ring strain. We are not aware of any precedent for such staffane fragmentation processes. Importantly, these experiments validate dihalides such as **18r**/**s** as alternative precursors to hetero[3.1.1]propellanes.

The preparation of bridge-substituted all-carbocyclic propellanes is very challenging, and it typically requires low-yielding and lengthy multistep sequences[41,42]. We were therefore pleased to find that variation of the exocyclic substituent on the nitrogen atom of 3-aza[3.1.1] propellanes is substantially easier, and can be achieved at a relatively late stage of the synthesis. Specifically (Fig. 3b), detosylation of the immediate aza-propellane precursor **17** using HBr and phenol, followed by reaction with a sulfonyl chloride, afforded quinoline, thiophene and bis-sulfonamide propellane precursors **20a**–**c**. We found that these compounds underwent smooth conversion to the corresponding propellanes **21a**–**c** in excellent yields on treatment with methyllithium (70–99%). Particularly notable is the highly efficient synthesis of the ‘double’ propellane **21c**, in which two ring-closing events are required. Generally, we observed that propellane formation proceeds optimally with electron-withdrawing substituents on the nitrogen atom, especially sulfonamides (details are provided in Supplementary Section 4), which opens up the possibility for further exploration of the scope of this substituent.

We were able to demonstrate the potential utility of these heterocyclic propellanes through a synthesis of the oxa-BCHep analogue of the anticancer drug sonidegib (**22**, Fig. 3c), which has been shown in previous work to display improved solubility and other physicochemical properties compared to the parent compound[15,16]. We found that ATRA adduct **18e** underwent iron-catalysed Kumada cross-coupling with *p*-trifluoromethoxy phenylmagnesium bromide[43], affording product **23** (49%). Elaboration of this product to the drug analogue was achieved by hydrolysis of the pivalate ester in **23**, then oxidation to acid **24** (46%); amide bond formation with amine **25** afforded oxa-BCHep sonidegib **22** (refs. 15,16) in 70% yield. Notably, our propellane-based strategy offers opportunities for late-stage variation of both the aromatic and amide parts of the drug analogue. Finally, to enhance opportunities for diversification of the *N*-sulfonyl propellane-derived 3-aza-BCHeps, we explored removal of the *N*-tosyl group resident in many of these products. After deiodination of aza-BCHep **18ac** (to intermediate **26**, Fig. 3d), we showed that detosylation could be effected under mild conditions (Mg, MeOH) to afford amine **27** in good yield (79%).

Discussion

Heterocyclic small-ring propellanes are now accessible via a concise, unified synthetic strategy that can be performed on a multigram scale. The synthesis hinges on an efficient rhodium-catalysed cyclopropanation of 2,3-dibromopropene that can be performed on a multidecagram scale due to the very low catalyst loading that is possible. This transformation establishes the first of the two cyclopropane rings in the heteropropellane target, and is followed by construction of the heterocyclic ring before the key formation of the second cyclopropane via metalation/cyclization. Crucially, the heteropropellanes can be directly isolated without need for distillation, and are found to be substantially more stable than their [3.1.1]propellane carbocyclic relative. These molecules display behaviour distinct from that of the latter well-known propellane, and are shown to offer direct access to valuable bridged heterocyclic small-ring building blocks that are of high interest in contemporary drug design via a range of radical ring-opening processes.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41557-026-02072-2.

References

1. Tsien, J., Hu, C., Merchant, R. R. & Qin, T. Three-dimensional saturated C(sp^3)-rich bioisosteres for benzene. *Nat. Rev. Chem.* **8**, 605–627 (2024).
2. Mykhailiuk, P. K. Saturated bioisosteres of benzene: where to go next?. *Org. Biomol. Chem.* **17**, 2839–2849 (2019).
3. Lovering, F., Bikker, J. & Humblet, C. Escape from flatland: increasing saturation as an approach to improving clinical success. *J. Med. Chem.* **52**, 6752–6756 (2009).
4. Fang, Z., Xu, Q., Lu, X., Wan, N. & Yang, W.-L. The application of bicyclo[1.1.1]pentane as a bioisostere of the phenyl ring in pharmaceutical chemistry. *Synthesis* **57**, 1171–1179 (2024).
5. Subbaiah, M. A. M. & Meanwell, N. A. Bioisosteres of the phenyl ring: recent strategic applications in lead optimization and drug design. *J. Med. Chem.* **64**, 14046–14128 (2021).
6. Stepan, A. F. et al. Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active gamma-secretase inhibitor. *J. Med. Chem.* **55**, 3414–3424 (2012).
7. Frank, N. et al. Synthesis of *meta*-substituted arene bioisosteres from [3.1.1]propellane. *Nature* **611**, 721–726 (2022).
8. Belzner, J. et al. Concerning the synthesis of [1.1.1]propellane. *Chem. Ber.* **122**, 397–398 (1989).
9. Gianatassio, R. et al. Organic chemistry. Strain-release amination. *Science* **351**, 241–246 (2016).
10. Shire, B. R. & Anderson, E. A. Conquering the synthesis and functionalization of bicyclo[1.1.1]pentanes. *JACS Au* **3**, 1539–1553 (2023).
11. He, F.-S., Xie, S., Yao, Y. & Wu, J. Recent advances in the applications of [1.1.1]-propellane in organic synthesis. *Chin. Chem. Lett.* **31**, 3065–3072 (2020).
12. Hu, Q.-Q., Chen, J., Yang, Y., Yang, H. & Zhou, L. Strain-release transformations of bicyclo[1.1.0]butanes and [1.1.1]propellanes. *Tetrahedron Chem* **9**, 100070 (2024).
13. Dilmac, A. M., Spuling, E., de Meijere, A. & Brase, S. Propellanes-from a chemical curiosity to ‘explosive’ materials and natural products. *Angew. Chem. Int. Ed.* **56**, 5684–5718 (2017).
14. Dibchak, D. et al. General synthesis of 3-azabicyclo[3.1.1]heptanes and evaluation of their properties as saturated isosteres. *Angew. Chem. Int. Ed.* **62**, e202304246 (2023).
15. Dibchak, D. & Mykhailiuk, P. 3-Oxabicyclo[3.1.1]heptane as an isostere of *meta*-benzene. *Angew. Chem. Int. Ed.* **64**, e202505519 (2025).
16. Morvan, J., Renders, E., Buijnsters, P. J. J. A. & Ryabchuk, P. 3-Oxabicyclo[3.1.1]heptanes as isosteres of *meta*-substituted benzene rings. *Org. Lett.* **27**, 3291–3295 (2024).
17. Wang, X., Gao, R. & Li, X. Catalytic asymmetric construction of chiral polysubstituted 3-azabicyclo[3.1.1]heptanes by copper-catalyzed stereoselective formal [4π+2σ] cycloaddition. *J. Am. Chem. Soc.* **146**, 21069–21077 (2024).
18. Liang, Y., Nematswerani, R., Daniliuc, C. G. & Glorius, F. Silver-enabled cycloaddition of bicyclobutanes with isocyanides for the synthesis of polysubstituted 3-azabicyclo[3.1.1]heptanes. *Angew. Chem. Int. Ed.* **63**, e202402730 (2024).
19. Lin, Z., Ren, H., Lin, X., Yu, X. & Zheng, J. Synthesis of azabicyclo[3.1.1]heptenes enabled by catalyst-controlled annulations of bicyclo[1.1.0]butanes with vinyl azides. *J. Am. Chem. Soc.* **146**, 18565–18575 (2024).
20. Dong, J., Liao, H. & Xue, D. Recent advances in the synthesis of bicyclo[3.1.1]heptanes. *Synthesis* **57**, 722–731 (2025).
21. Feng, J.-J. Recent progress in (3+3) cycloadditions of bicyclobutanes to access bicyclo[3.1.1]heptane derivatives. *Synlett* **36**, 621–629 (2025).
22. Dutta, S., Daniliuc, C. G., Mück-Lichtenfeld, C. & Studer, A. Formal [2σ+2σ]-cycloaddition of aziridines with bicyclo[1.1.0]butanes: access to enantiopure 2-azabicyclo[3.1.1]heptane derivatives. *J. Am. Chem. Soc.* **146**, 27204–27212 (2024).
23. Zhou, J.-L. et al. Palladium-catalyzed ligand-controlled switchable hetero-(5+3)/enantioselective [2σ+2σ] cycloadditions of bicyclobutanes with vinyl oxiranes. *J. Am. Chem. Soc.* **146**, 19621–19628 (2024).
24. Xiao, Y. et al. Divergent synthesis of sulfur-containing bridged cyclobutanes by Lewis acid catalyzed formal cycloadditions of pyridinium 1,4-zwitterionic thiolates and bicyclobutanes. *Angew. Chem. Int. Ed.* **63**, e202408578 (2024).
25. Zhang, J., Su, J.-Y., Zheng, H., Li, H. & Deng, W.-P. Eu($OTf)_3$-catalyzed formal dipolar [4π+2σ] cycloaddition of bicyclo-[1.1.0]butanes with nitrones: access to polysubstituted 2-oxa-3-azabicyclo[3.1.1]heptanes. *Angew. Chem.* **136**, e202318476 (2024).
26. Wu, W.-B. et al. Enantioselective formal (3+3) cycloaddition of bicyclobutanes with nitrones enabled by asymmetric Lewis acid catalysis. *Nat. Commun.* **15**, 8005 (2024).
27. Zhang, X.-G., Zhou, Z.-Y., Li, J.-X., Chen, J.-J. & Zhou, Q.-L. Copper-catalyzed enantioselective [4π+2σ] cycloaddition of bicyclobutanes with nitrones. *J. Am. Chem. Soc.* **146**, 27274–27281 (2024).
28. Dhake, K. et al. Diastereoselective dearomative cycloaddition of bicyclobutanes with pyridinium ylides: a modular approach to multisubstituted azabicyclo[3.1.1]heptanes. *Chem. Commun.* **60**, 13008–13011 (2024).
29. Sterling, A. J., Dürr, A. B., Smith, R. C., Anderson, E. A. & Duarte, F. Rationalizing the diverse reactivity of [1.1.1]propellane through σ–π-delocalization. *Chem. Sci.* **11**, 4895–4903 (2020).
30. Kaszynski, P., McMurdie, N. D. & Michl, J. Synthesis of doubly bridgehead substituted bicyclo[1.1.1]pentanes. Radical transformation of bridgehead halides and carboxylic acids. *J. Org. Chem.* **56**, 307–316 (1991).
31. Caputo, D. F. J. et al. Synthesis and applications of highly functionalized 1-halo-3-substituted bicyclo[1.1.1]pentanes. *Chem. Sci.* **9**, 5295–5300 (2018).
32. Nugent, J. et al. A general route to bicyclo[1.1.1]pentanes through photoredox catalysis. *ACS Catal.* **9**, 9568–9574 (2019).
33. Pickford, H. D. et al. Twofold radical-based synthesis of *N*,*C*-difunctionalized bicyclo[1.1.1]pentanes. *J. Am. Chem. Soc.* **143**, 9729–9736 (2021).
34. Pickford, H. D. et al. Rapid and scalable halosulfonylation of strain-release reagents. *Angew. Chem. Int. Ed.* **62**, e202213508 (2023).
35. Nugent, J. et al. α-amino bicycloalkylation through organophotoredox catalysis. *Chem. Sci.* **15**, 10918–10925 (2024).

36. Bär, R. M., Kirschner, S., Nieger, M. & Bräse, S. Alkyl and aryl thiol addition to [1.1.1]propellane: scope and limitations of a fast conjugation reaction. *Chem. Eur. J.* **24**, 1373–1382 (2018).
37. Wiberg, K. B., Waddell, S. T. & Laidig, K. [1.1.1]Propellane: reaction with free radicals. *Tetrahedron Lett.* **27**, 1553–1556 (1986).
38. Wu, Z., Xu, Y., Wu, X. & Zhu, C. Synthesis of selenoether and thioether functionalized bicyclo[1.1.1]pentanes. *Tetrahedron* **76**, 131692 (2020).
39. Iida, T. et al. Practical and facile access to bicyclo[3.1.1]heptanes: potent bioisosteres of *meta*-substituted benzenes. *J. Am. Chem. Soc.* **144**, 21848–21852 (2022).
40. Adcock, J. L. & Gakh, A. A. Nucleophilic substitution in 1-substituted 3-iodobicyclo[1.1.1]pentanes. A new synthetic route to functionalized bicyclo[1.1.1]pentane derivatives. *J. Org. Chem.* **57**, 6206–6210 (1992).
41. Bothe, H. & Schl üter, A.-D. Synthesis of monosubstituted [1.1.1] propellanes. *Chem. Ber.* **124**, 587–590 (1991).
42. Zhao, J.-X. et al. 1,2-Difunctionalized bicyclo[1.1.1]pentanes: long-sought-after mimetics for *ortho*/*meta*-substituted arenes. *Proc. Natl Acad. Sci. USA* **118**, e2108881118 (2021).
43. Nugent, J. et al. Synthesis of all-carbon disubstituted bicyclo[1.1.1] pentanes by iron-catalyzed Kumada cross-coupling. *Angew. Chem. Int. Ed.* **59**, 11866–11870 (2020).

Methods

Dimethyl 2-diazomalonate (6)

To a solution of dimethyl malonate (17.3 ml, 151 mmol, 1.0 equiv.) and 4-acetamidobenzenesulfonyl azide (40.0 g, 167 mmol, 1.1 equiv.) in dry MeCN (150 ml) at 0 °C was added 1,8-diazabicycloundec-7-ene (24.9 ml, 167 mmol, 1.1 equiv.) dropwise over 30 min, keeping the internal temperature below 20 °C. The mixture was then warmed to room temperature (r.t.) and stirred for 3 h. NH_4Cl sat. (20 ml) was added, then the solvent was removed under reduced pressure. Water (400 ml) was added and the mixture was extracted with Et_2O (3 × 400 ml), then the combined organic layers were washed with brine (600 ml), dried over anhydrous $MgSO_4$, filtered and concentrated under reduced pressure. The mixture was filtered through a silica plug and eluted with a 4:1 mixture of hexane/EtOAc until all of the yellow substance was removed from the silica. Concentration under reduced pressure gave the product (20.6 g, 130 mmol, 86%) as a yellow oil. For safety reasons, to avoid isolation of neat diazo compound, the product is not concentrated until completely free of solvent, but is taken forward to the next step with ~10% residual solvent remaining. The proportion of product in the isolated mixture was determined by NMR spectroscopy.

Dimethyl 2-bromo-2-(bromomethyl)cyclopropane-1,1-dicarboxylate (7)

To a solution of rhodium(II) triphenylacetate dimer (93.8 mg, 65.1 μmol, 0.050 mol%) in dry CH_2Cl_2 (100 ml) was added 2,3-dibromoprop-1-ene (25.5 ml, 80%, 208 mmol, 1.6 equiv.). A solution of dimethyl 2-diazomalonate **6** (20.6 g, 130 mmol, 1.0 equiv.) in dry CH_2Cl_2 (20.0 ml) was added via a syringe pump over 8 h at r.t. then the mixture was stirred at r.t. for an additional 8 h. The solvent was removed under reduced pressure, then purification by column chromatography (SiO_2, pentane/Et_2O 19:1 → 8:2) gave the product (29.1 g, 88.2 mmol, 68%) as a colourless oil.

(5-Bromo-3-oxabicyclo[3.1.0]hexan-1-yl)methanol (9)

To a solution of **7** (15.0 g, 46.0 mmol, 1.0 equiv.) in dry THF (150 ml) at −78 °C was added DIBALH (200 ml, 1.0 M solution in hexanes, 200 mmol, 4.3 equiv.). The mixture was stirred at −78 °C for 2.5 h, allowed to warm slowly to r.t. and stirred for an additional 30 min. The mixture was cooled to 0 °C, and Rochelle's salt (250 ml, aq. sat.) was added slowly. The cloudy mixture was stirred at r.t. for 5 h until it became clear. THF was removed under reduced pressure, then the aqueous layer was extracted with EtOAc (3 × 200 ml). The combined organic layers were washed with brine (300 ml), dried over anhydrous $MgSO_4$, filtered, and concentrated under reduced pressure to afford (2-bromo-2-(bromomethyl)cyclopropane-1,1-diyl)dimethanol (**8**).

The crude product **8** from the first step was dissolved in MeOH (100 ml) and added to a solution of KOH (4.50 g, 80.0 mmol, 1.8 equiv.) in MeOH (150 ml). The mixture was heated to 60 °C for 1 h, then the solvent was removed under reduced pressure. Water (100 ml) was added and the mixture was extracted with Et_2O (3 × 100 ml). The combined organic layers were dried over anhydrous $MgSO_4$, filtered, and concentrated under reduced pressure to give product **9** (7.40 g, 38.0 mmol, 84%) as a yellow oil, which required no further purification.

(2-Bromo-2-(bromomethyl)cyclopropane-1,1-diyl) dimethanol (8)

To a solution of **7** (6.69 g, 20.3 mmol, 1.0 equiv.) in dry THF (50.0 ml) at −78 °C was added DIBALH (83.1 ml, 1.0 M solution in hexanes). The mixture was stirred at −78 °C for 2 h, then stirred at 0 °C for a further 1 h. Rochelle's salt (100 ml, aq. sat.) was added, and the cloudy mixture was stirred at r.t. for 3 h until it became clear. THF was removed under reduced pressure, then the aqueous layer was extracted with EtOAc (3 × 100 ml). The combined organic layers were washed with brine (100 ml), dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure. Trituration from a 7:3 mixture of pentane:Et_2O gave the product (2.59 g, 9.45 mmol, 47%) as a white amorphous solid, which was collected by filtration.

1-Bromo-5-(bromomethyl)-3-oxabicyclo[3.1.0]hexane (10)

To a solution of **9** (7.59 g, 39.3 mmol, 1.0 equiv.) in dry CH_2Cl_2 (100 ml), was added *N*-bromosuccinimide (NBS; 8.40 g, 47.2 mmol, 1.2 equiv.). PPh_3 (12.4 g, 47.2 mmol, 1.2 equiv.) was then added in portions at 0 °C, and the mixture was stirred at r.t. for 1 h. Pentane (150 ml) was added to the reaction mixture and stirred for 10 min at r.t. The mixture was filtered through a celite pad, and the filtrate was concentrated. Purification by column chromatography (SiO_2, pentane/Et_2O 19:1) gave the product (7.43 g, 29.0 mmol, 74%) as a pale yellow oil. This compound is relatively volatile and must be concentrated carefully with pressure not lower than 250 mbar. However, we have not observed any stability issues with the storage of this propellane precursor over a period of several months.

3-Oxa[3.1.1]propellane (3)

To a stirred solution of **10** (5.03 g, 15.7 mmol, 1.0 equiv.) in dry Et_2O (80 ml) at r.t. was added MeLi (12.1 ml, 1.3 M in Et_2O, 15.7 mmol, 1.0 equiv.). The mixture was stirred at r.t. for 4 h, then $NaHCO_3$ (1.32 g, 15.7 mmol, 1.0 equiv.) was added. The mixture was cooled to 0 °C, then passed through a celite pad and eluted with Et_2O (100 ml). The mixture was partially concentrated under reduced pressure to give the product as a solution in Et_2O (72.0 ml, 0.16 M, 11.7 mmol, 74%), which was stored in an amber glass bottle with an AcroSeal under N_2 at −20 °C (caution: during the partial concentration process, bromomethane will be released). The concentration was determined by integrating the ^1H NMR peak at 2.51 ppm relative to the Et_2O peaks. The solution of product contains a white precipitate, presumed to be LiBr, which does not affect subsequent reactions. It is recommended to store the propellane solution in the freezer (−20 °C) at <0.5 M concentration, under which conditions it is stable for a period of (at least) several weeks to months.

The propellane **3** can also be isolated by distillation according to the following procedure. To a stirred solution of **10** (1.02 g, 3.19 mmol, 1.0 equiv.) in dry Et_2O (16 ml) at r.t. was added MeLi (2.45 ml, 1.3 M in Et_2O, 3.19 mmol, 1.0 equiv.). The mixture was stirred at r.t. for 4 h, then $NaHCO_3$ (268 mg, 3.19 mmol, 1.0 equiv.) was added. $^nBu_2O$ (30 ml) was added and the mixture was distilled using a rotary evaporator (30 °C water bath) with a dry-ice cold finger condenser and a receiving flask immersed in an acetone/dry-ice bath. The Et_2O fraction containing bromomethane was removed by slowly decreasing the pressure to 150 mbar and this fraction was discarded. The $^nBu_2O$ fraction containing 3-oxa[3.1.1]propellane was then distilled by slowly decreasing the pressure to <10 mbar. This gave the product as a solution in $^nBu_2O$ (27.0 ml, 0.065 M, 1.76 mmol, 55%), which was stored in an amber bottle with an AcroSeal under N_2 at −20 °C. The concentration was determined by integrating the ^1H NMR peak at 2.42 ppm relative to the Et_2O peaks.

3-Thia[3.1.1]propellane (4)

To a stirred solution of **13** (0.961 g, 3.53 mmol, 1.0 equiv.) in dry Et_2O (18 ml) at r.t. was added MeLi (2.72 ml, 1.3 M in Et_2O, 3.53 mmol, 1.0 equiv.). The mixture was stirred at r.t. for 4 h, then $NaHCO_3$ (297 mg, 3.53 mmol, 1.0 equiv.) was added. The mixture was cooled to 0 °C, then passed through a celite pad and eluted with Et_2O (50 ml). The mixture was partially concentrated under reduced pressure to give the product as a solution in Et_2O (18.5 ml, 0.13 M, 2.41 mmol, 68%), which was stored in an amber glass bottle with an AcroSeal under N_2 at −20 °C. The concentration was determined by integrating the ^1H NMR peak at 2.79 ppm relative to the Et_2O peaks. It is recommended to store the propellane solution in the freezer (−20 °C) at <0.5 M concentration, under which conditions it is stable for a period of (at least) several weeks to months.

3-(*N*-tosyl)aza[3.1.1]propellane (5)

To a stirred solution of **17** (2.00 g, 4.89 mmol, 1.0 equiv.) in dry THF (40 ml) at −78 °C was added MeLi (3.76 ml, 1.3 M in Et_2O, 4.89 mmol, 1.0 equiv.). The mixture was stirred at −78 °C for 10 min then at r.t. for 1 h. $NaHCO_3$ (411 mg, 4.89 mmol, 1.0 equiv.) was added, then the mixture was cooled to 0 °C, passed through a celite pad and eluted with THF (100 ml). The mixture was partially concentrated under reduced pressure to give the product as a solution in THF (26.0 ml, 0.18 M, 4.79 mmol, 98%), which was stored in an amber glass bottle with an AcroSeal under N_2 at −20 °C. The concentration was determined by integrating the ^1H NMR peak at 3.17 ppm relative to the THF peaks. It is recommended to store the propellane solution in the freezer (−20 °C) at <0.5 M concentration, under which conditions it is stable for a period of (at least) several weeks to months.

Data availability

Supplementary Information is available for this paper (experimental procedures, X-ray crystallographic data (.cif file), copies of NMR spectra). Crystallographic data for the structures reported in this article have been deposited at the Cambridge Crystallographic Data Centre, under deposition numbers CCDC 2412510 and 2412511. Copies of the data can be obtained free of charge via https://www.ccdc.cam.ac.uk/structures.

Acknowledgements

R.I.R. and E.A.A. thank AbbVie for support. A.D. and E.A.A. thank the Engineering and Physical Sciences Research Council (EPSRC) for support (EP/S013172/1). We gratefully acknowledge the EPSRC for a Strategic Equipment Grant (EP/V028995/1) and A. L. Thompson for assistance. We are also grateful to AbbVie for further contributions, specifically A. H. Kaffka for assistance with the DSC analysis described in Supplementary Section 6.

Author contributions

E.A.A., R.I.R. and R.C.S. conceived of the project. Experimental work was carried out by R.I.R. and A.D. X-ray diffraction data were acquired and solved by Y.B. and K.E.C. The project was supervised by E.A.A. E.A.A. and R.I.R. wrote and edited the paper.

Competing interests

A patent has been filed by E.A.A. and R.I.R. (UK Patent application no. 2415923.8, granted) that covers all of the research described in this paper. The other authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41557-026-02072-2.

Correspondence and requests for materials should be addressed to Edward A. Anderson.

Peer review information *Nature Chemistry* thanks David Leitch, Tian Qin and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.